Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|AMV-564||AMV564|AMV 564||CD3 Antibody 20 CD33 Antibody 11||AMV-564 is a tandem diabody that targets both CD33 and CD3, which may result in increased T-cell activation and death of CD33-expressing tumor cells (PMID: 27189165, PMID: 28157217).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03144245||Phase I||AMV-564||Study of AMV564 in Patients With AML||Active, not recruiting|
|NCT04128423||Phase I||AMV-564||Study of AMV564 in Subjects With Advanced Solid Tumors||Recruiting|
|NCT03516591||Phase I||AMV-564||A Phase 1 Study of AMV564 in Patients With Intermediate or High-Risk Myelodysplastic Syndromes||Active, not recruiting|